March 10 (Reuters) -
BioNTech SE <22UAy.DE>::
*EXPECTS 2025 TOTAL REVENUES BETWEEN EUR 1.7 BILLION AND EUR 2.2 BILLION
*CASH AND CASH EQUIVALENTS PLUS SECURITY INVESTMENTS OF EUR 17.4 BILLION AS OF DECEMBER 31, 2024
*CEO - EXPECT 2025 TO BE A DATA-RICH YEAR WITH MULTIPLE IMPORTANT UPDATES FROM OUR PRIORITY PROGRAMS, WHICH WE BELIEVE HAVE DISRUPTIVE POTENTIAL AND COULD IMPROVE STANDARD OF CARE, IF SUCCESSFULLY DEVELOPED AND APPROVED
*OUTLOOK 2025: RESEARCH AND DEVELOPMENT EXPENSES EUR 2,600 MILLION - EUR 2,800 MILLION, SG&A EXPENSES EUR 650 MILLION - EUR 750 MILLION
*OUTLOOK 2025: CAPITAL EXPENDITURES FOR OPERATING ACTIVITIES EUR 250 MILLION - EUR 350 MILLION
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 10-MAR-202510:55:00.233 GMT
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。